Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Advance Cancer Treatment
Johnson & Johnson acquires Halda Therapeutics for $3.05B, gaining innovative prostate cancer treatment and platform technology for multiple solid tumors.
/ 7 items
#JNJ↓
Bristol Myers & J&J Halt Key Heart Drug Trial After Weak Results
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
Novartis Makes Bold $12 Billion Move with Avidity Biosciences Acquisition in Largest Deal Under CEO Narasimhan
Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.
Johnson & Johnson Spins Off DePuy Synthes Amid Pricing Pressure and Strategic Focus on High-Growth Markets
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.
J&J Looks to Acquire Protagonist to Bolster Pipeline Amid Stelara Competition
Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.
Massive New Tariffs: How Trump’s Latest Duties Hit Drugs, Trucks, and Furniture
President Trump is hitting imports with massive new tariffs starting October 1st, targeting branded drugs (100%), heavy trucks (25%), and furniture.